Early detection of Alzheimer’s disease relies heavily on accurate quantification of phosphorylated Tau species in blood plasma. In this technical validation, Renduan Biomed’s recombinant p-Tau217 monoclonal antibodies were evaluated across clinical EDTA plasma matrices. Results show excellent linearity (R² > 0.998) and a limit of detection (LOD) below 0.2 pg/mL, providing high reliability for diagnostic reagent developers.